Condition: Advanced Endometrial Cancer · Sponsor: Hutchmed
The goal of this study is to evaluate whether fruquintinib(HMPL-013) plus sintilimab(IBI308) is safe and effective in the treatment of advanced endometrial cancer(EMC).
This description comes directly from the study's public registry record.
Panfeng Tan · 86-21-20671828 · panfengt@hutch-med.com
Always discuss trial participation with your own doctor first.
| Beijing Obstetrics and Gynecology Hospital | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Chongqing Cancer Hospital | Chongqing, Chongqing Municipality, China | Not Yet Recruiting |
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Not Yet Recruiting |
| SUN Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Guangxi Medical University Cancer Hospital | Nanning, Guangxi, China | Recruiting |
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang, China | Not Yet Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Recruiting |
| Hunan Cancer Hospital | Changsha, Hunan, China | Not Yet Recruiting |
| Xijing Hospital of Air Force Military Medical University | Xi'an, Shaanxi, China | Not Yet Recruiting |
| Shandong Cancer Hospital | Jinan, Shandong, China | Not Yet Recruiting |
| Fudan University Shanghai Cancer Center | Shanghai, Shanghai Municipality, China | Recruiting |
| Sencond Hospital of Shanxi Medical University | Taiyuan, Shanxi, China | Not Yet Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06584032